Protocol Ledger

NCT05686642 · Phase II · RECRUITING

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Interventional Phase II clinical trial protocol NCT05686642 sponsored by Shanghai Pharmaceuticals Holding Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-06 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05686642
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05686642
Protocol FieldVerified Registry Value
NCT IdentifierNCT05686642
Consolidated Lead SponsorShanghai Pharmaceuticals Holding Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2023-04-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05686642
Hospital Research SiteLocationSite Profile
Zhongnan Hospital of Wuhan UniversityWuhan, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI